EYPT
Eyepoint Pharmaceuticals Inc
3.30$
+0.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 92.2% | 92.2% | 95.0% | 95.0% | 55.7% | 57.2% | 68.8% | 90.3% | 95.8% | 97.1% | 91.6% | 90.3% | |
| 59.1% | 47.3% | 90.5% | 90.5% | 54.1% | 30.4% | 49.0% | 67.8% | 53.0% | 79.2% | 23.8% | 28.0% | |
| 88.2% | 89.6% | 90.5% | 90.5% | 54.1% | 30.4% | 49.0% | 80.3% | 80.2% | 93.2% | 88.6% | 84.1% | |
| 1.9% | 1.5% | 1.3% | 1.3% | 0.5% | 15.6% | 10.3% | 7.0% | 8.6% | 0.2% | 0.1% | 0.2% | |
| 0.0% | -1.9% | -2.6% | -1.3% | -0.5% | 2.9% | 5.8% | 1.4% | 1.6% | 1.1% | 0.6% | 0.5% | |
| 1.0% | 0.9% | 1.7% | 1.4% | 0.4% | 0.5% | 0.7% | 0.9% | 0.8% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 8.5% | 5.9% | 5.9% | 1.9% | 43.8% | 37.9% | 27.5% | 8.6% | – | – | – | – | |
| 27.8% | 33.2% | 28.6% | 28.6% | 83.7% | 88.6% | 79.8% | 30.0% | 46.6% | 25.0% | 19.6% | 15.9% | |
| 10.3% | 15.7% | 28.3% | 28.3% | 30.2% | 15.8% | 16.2% | 9.0% | 19.1% | 17.8% | 11.7% | 10.2% | |
| – | – | – | 92.7% | 0.0% | 0.7% | 9.2% | 0.3% | 6.1% | 0.2% | 0.3% | 0.6% | |
| 2.3% | 4.2% | 5.4% | 5.4% | 9.3% | 5.7% | 5.2% | 2.8% | 3.3% | 1.8% | 2.8% | 2.9% | |
| 0.0% | 0.0% | 0.0% | 92.7% | 24.6% | 64.7% | 41.4% | 13.9% | 16.3% | – | – | – | |
| 72.2% | 64.5% | 71.4% | 71.4% | 16.3% | 11.4% | 20.2% | 70.0% | 53.4% | 75.0% | 80.4% | 84.1% | |
| -836.2% | -902.8% | -1,664.2% | -1,664.2% | -507.9% | -637.6% | -556.8% | -216.1% | -372.2% | -208.9% | -208.6% | -303.6% | |
| 8.5% | 9.4% | 16.9% | 18.9% | 6.4% | 14.3% | 14.0% | 10.9% | 20.7% | 11.0% | 13.5% | 20.1% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.